Navigation Links
MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna(R) Reduces Key Marker of Kidney Disease
Date:6/4/2008

Diabetes and high blood pressure are the leading causes of kidney disease, which affects approximately 26 million people in the United States. For patients with high blood pressure and type 2 diabetes, reducing proteinuria is associated with slowing the progression of kidney disease, which can reduce the risk of kidney failure. There are approximately 14 million adults in the US diagnosed with diabetes and high blood pressure.

Data published in this week's New England Journal of Medicine demonstrate that the first direct renin inhibitor Tekturna (aliskiren), when added to the maximum dose of the angiotensin-receptor-blocker (ARB) losartan, reduced proteinuria, a key indicator of kidney disease, independent of its already proven ability to provide powerful blood pressure reductions. Damage to the kidneys caused by diabetes is the leading cause of end-stage renal disease in developed countries, affecting more than 1.5 million people worldwide.

In the AVOID (Aliskiren in the EValuation of PrOteinuria In Diabetes) study, Tekturna, when added to the maximum dose of losartan, reduced proteinuria by 20% compared to losartan alone in patients diagnosed with high blood pressure and type 2 diabetes. These patients were initially treated with the maximum dose of losartan, which has been shown to slow the progression of diabetic kidney disease.

Tekturna, the latest type of high blood pressure medication, works differently from other high blood pressure medications by targeting renin, an enzyme that starts a process that when inappropriately activated may lead to high blood pressure.

About Tekturna

Tekturna is a prescription medication for adults, used to treat high blood pressure. It can be used alone or in combination with other high blood pressure medications. Tekturna has not been adequately studied in combination with the maximum doses of a class of medications called ACE inhibitors.

Important Considerations:

IMPORTANT
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. MultiVu Video Feed: FREE NICOTINE REPLACEMENT THERAPY (NRT) TO BE OFFERED TO REGISTERED PILOTS INTERESTED IN QUITTING RELIEF IN LIGHT OF RECENT FAA RULINGS
2. MultiVu Video Feed: Richard Simmons and Ocean Spray Team-Up to Solve
3. MultiVu Video Feed: Podiatrists Keep America Walking
4. MultiVu Video Feed: Stinky Sneakers Worth Big Money!
5. MultiVu Video Feed: New National Colorectal Cancer Screening Guidelines Issued by the American Cancer Society
6. MultiVu Video Feed: LIFE AND STYLE EXPERT SANDRA LEE OFFERS RECIPES AND SHORTCUTS IN THE KITCHEN TO PEOPLE WITH RHEUMATOID ARTHRITIS
7. MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS
8. Photo: MultiVu Promotes George DeTorres to Divisional Vice President for the MultiVu Healthcare Team
9. MultiVu Video Feed: NEW SURVEY FINDS THAT HALF OF CAREGIVERS SPEND 10 PERCENT OF THEIR INCOME CARING FOR AN OLDER LOVED ONE
10. MultiVu Video Feed: STARLIGHT STARBRIGHT UNVEILS GET FIT, GET RIGHT A PROGRAM TO PREVENT TYPE 2 DIABETES AND WEIGHT-RELATED CONDITIONS IN TEENS
11. MultiVu Video Feed: Parents of Kids With Infectious Diseases Sounds Alarm About the Dangers of Pertussis With "Silence the Sounds of Pertussis" Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2008)... Byetta has also been linked recently to patient d...s) -- A new once-a-week formulation of the injecta... better than the older twice-a-day formulation, re...ase of use, [the new formulation] provided the rem...cose control and good gastrointestinal tolerabilit...
(Date:9/5/2008)... HARRISBURG, Pa., Sept. 5 /PRNewswire-USNewswire/ ... issued a proclamation acknowledging Sept. 11 as,A...lth of Pennsylvania and The American Red Cross ask...oration of those who lost their,lives on 9/11 and ...lood,donation can save up to three lives., "We al...
(Date:9/5/2008)...earchers explain how theoretical ,anti-cloak, coul..., Sept. 5 (HealthDay News) -- Just in case someone...se scientists say they know how to uncloak the obj... in Optics Express , certain materials underneath...ts to be seen again. , Researchers at Shanghai ...
(Date:9/5/2008)... FRANKLIN, Mass., Sept. 5 /PRNewswire/ -- Arthrosu...developer of less-invasive joint,resurfacing syste...he U.S.,FDA to begin its pivotal investigation for...FDA stated that "there are no outstanding safety,c...tiation., Arthrosurface has been evaluating the s...
Breaking Medicine News(10 mins):Health News:Once-Weekly Diabetes Drug Boosts Blood Sugar Control 2Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2
...ge that victims of the terrible 'Elephant Man' cli... a 'reckless' rate.// The drug, a monoclonal anti...mia, multiple sclerosis and rheumatoid arthritis. ...t the victims had been injected 15 times faster th...
...lf of all children in the most rural counties of t...eas, according to a new study //by HHS Agency for ...published in the September-October 2006 issue of A... was led by AHRQ’s Frances Chevarley, Ph.D., analy...
...s can be treated with a low-priced antibiotic, acc...the limbs or scrotum. // A team of scientists at t...t doxycycline gave some relief to patients in the ...e. In addition, the antibiotic killed the causativ...
...earch has revealed that it is tougher to quit ment...be the reason for the excessive smoking-related di...lished in the Archives of Internal Medicine.Nearly...thol cigarettes like Kool or Newport in comparison...
Other Medicine News:Health News:Catastrophic Elephant Man Drug Trial Victims Injected Recklessly 2Health News:Local Health Care Limited for Rural Children 2Health News:Menthol cigarettes harder to quit than regular cigarettes 2
(Date:9/6/2008)...cent or Greater Concordance Compared to FISH ... - Company to Include Reporting for HER2 Gene Expr...eports by End of 2008 -, REDWOOD CITY, Calif., Se...c. (Nasdaq: GHDX ) today announced results from t...ng for HER2 gene expression, as measured by the,co...
(Date:9/5/2008)...PRNewswire-USNewswire/ -- The Florida,Technology, ...orida,Atlantic University researcher Dr. Herbert W...the Center for Molecular Biology and,Biotechnology... CHS,Resources LLC (CHS), $184,294 as part of the ...ance Grant program (SURECAG). SURECAG was,establis...
(Date:9/5/2008)..., Sept. 5 /- SARcode,Corpor... LFA-1 inhibitors,to treat inflammatory diseases, ...oday announced SARcode,s initiation of a Phase 1 c...ndidate for T-cell mediated ophthalmic,diseases. S...t providing,SARcode with an exclusive license to S...
(Date:9/4/2008)... 4 /- Cytopia Limited (ASX:,CYT) toda...s Phase Ib/II,study of CYT997, the company,s novel... with an aggressive form of brain cancer known as ...trial is the first Phase II efficacy study in high...ny and the second in its,suite of Phase II studies...
Breaking Medicine Technology:Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 2Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 5Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3Medgate Selected by NASA to Deliver Health and Safety Software Solutions 23181 1Back From the Dead 3A Cardiac Arrest Victim Salutes His Rescuer 23177 1Back From the Dead 3A Cardiac Arrest Victim Salutes His Rescuer 23177 2Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 1Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 2Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 3New Hope Against the Cold Sore Virus 23170 1New Hope Against the Cold Sore Virus 23170 2New Hope Against the Cold Sore Virus 23170 3
Transcranial vascular DWL doppler.
Transcranial vascular DWL doppler.
Transcranil vascular DWL doppler.
...m Viasys Neurocare is a full-featured physiologic ...table size. It contains many of the features of ou...t an economical price. , ,The smaller size of ...ironment, the physician's office, a mobile service...
Medicine Products: